Form 4: Alignment Healthcare CEO Sells 90,000 Shares Under 10b5-1 Plan

Alignment Healthcare's CEO, John E. Kao, sold 90,000 shares of common stock at $13.4216 per share under a pre-arranged 10b5-1 trading plan.

Summary

• John E. Kao, the CEO of Alignment Healthcare, sold 90,000 shares of the company's common stock on November 11, 2024.
• The sale was executed at a price of $13.4216 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2024.
• Following the sale, Mr. Kao directly owns 2,745,253 shares and indirectly owns 2,453,100 shares through the JEK Trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan. It is neither particularly positive nor negative.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Industry Context

Executive stock sales are a common occurrence, especially under pre-arranged trading plans like 10b5-1 plans, which allow insiders to sell shares while avoiding accusations of trading on non-public information. This is a routine transaction and does not necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• Executive stock sales are a common practice across publicly traded companies, particularly in the healthcare sector.
• Many CEOs and other high-ranking executives use 10b5-1 plans to manage their personal finances and avoid potential insider trading issues.
• Comparable companies such as Humana, UnitedHealth Group, and CVS Health also see similar transactions from their executives.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but it is unlikely to have a significant effect on the company's operations or financial health.

Key Dates

Keywords

stock sale, insider trading, 10b5-1 plan, executive, Alignment Healthcare, ALHC, John E. Kao